menu
    • menu

    Company profile for BrainStorm Cell Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as ALS (Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD). These diseases have limited treatment options and as such represent unmet medical needs. NurOwn™ is BrainStorm’s proprietary process for the propagation...
    BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as ALS (Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD). These diseases have limited treatment options and as such represent unmet medical needs. NurOwn™ is BrainStorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BrainStorm Cell TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3 University Plaza Drive Suite 320 Hackensack, NJ 07601
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://brainstorm-cell.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/brainstorm-cell-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/BrainStormCell

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Brainstorm Cell Therapeutics Reveals Q3 2025 Financials Update
    Brainstorm Cell Therapeutics Reveals Q3 2025 Financials Update

    15 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-third-quarter-2025-financial-results-and-provides-corporate-update-302615557.html

    PR NEWSWIRE
    15 Nov 2025
    Share Share
    BrainStorm to Report Q2 Financial Results and Corporate Update
    BrainStorm to Report Q2 Financial Results and Corporate Update

    08 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/brainstorm-to-announce-second-quarter-financial-results-and-provide-a-corporate-update-302524833.html

    PR NEWSWIRE
    08 Aug 2025
    Share Share
    BrainStorm Cell Therapeutics shifts to OTCQB from Nasdaq
    BrainStorm Cell Therapeutics shifts to OTCQB from Nasdaq

    17 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-nasdaq-delisting-and-transition-to-otcqb-302508133.html

    PR NEWSWIRE
    17 Jul 2025
    Share Share
    BrainStorm's ALS Drug Access Fought for By Patients Post
    BrainStorm's ALS Drug Access Fought for By Patients Post

    17 Jul 2025

    // BIOSPACE

    https://www.biospace.com/policy/patients-fight-for-access-to-brainstorms-als-drug-after-expanded-access-data-defy-logic

    BIOSPACE
    17 Jul 2025
    Share Share
    FDA Reevaluates NurOwn®'s Treatment Effectiveness Evidence
    FDA Reevaluates NurOwn®'s Treatment Effectiveness Evidence

    09 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-review-of-citizen-petition-offers-a-fresh-look-at-nurowns-evidence-of-treatment-effectiveness-302500016.html

    PR NEWSWIRE
    09 Jul 2025
    Share Share
    ALS Advocates Urge FDA Review of BrainStorm NurOwn Data
    ALS Advocates Urge FDA Review of BrainStorm NurOwn Data

    08 Jul 2025

    // BIOSPACE

    https://www.biospace.com/fda/als-patients-petition-fda-to-reconsider-brainstorms-nurown-pointing-to-recent-survival-data

    BIOSPACE
    08 Jul 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search